Jury finding upends Bayer's Roundup defense strategy: experts

Bayer shares tumbled more than 12 percent on Wednesday after a unanimous jury in San Francisco federal court found Roundup to be a "substantial factor" in causing California resident Edwin Hardeman's non-Hodgkin's lymphoma.The jury decision was a blow to Bayer after the judge in the Hardeman case, at the company's request, had split the trial, severely limiting evidence plaintiffs could present in the first phase.Tuesday's defeat on terms considered advantageous to Bayer sets up the second phase